SueWallSt

Dive into the latest episode of Sue Wall Street where we unravel the class action lawsuit against $CHTR Charter Communications. If you’re an investor, trader, or anyone tracking broadband giants, this one’s for you. We break down how the collapse of a key federal internet subsidy program triggered massive customer losses and what the company allegedly hid from shareholders. Expect sharp banter, deep dives, and no fluff.
Visit ZLK.com for more info.Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Unicycive Therapeutics $UNCY claimed it was “very, very much ready” to launch its kidney disease drug—until back-to-back FDA setbacks tanked the stock by over 70 percent. In this episode of Sue Wall Street, Cassie and Bill unravel the lawsuit alleging executives misled investors about manufacturing readiness and FDA approval chances. Ideal for biotech watchers, retail investors, and class action followers. Expect sharp commentary, SEC breakdowns, and real accountability.
Visit ZLK.com for more info.
Join our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

C3ai $AI is in hot water after investors say the company misled them about CEO health issues and inflated revenue expectations leading to a 25 percent stock crash. In this episode of Sue Wall Street, Cassie and Bill break down the lawsuit alleging securities fraud and explain what really went down behind those bullish earnings calls. Perfect for retail investors, finance followers, and anyone tracking AI stocks. Expect deep dives, drama, and analysis with bite.
Visit ZLK.com for more info.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Capricor Therapeutics $CAPR claimed its miracle drug for Duchenne muscular dystrophy was cruising toward FDA approval. But behind the scenes? Alleged data concealment, canceled advisory meetings, and a crushing FDA rejection. In this episode of Sue Wall Street, Cassie and Bill unravel the class action lawsuit and the biotech optimism that may have misled investors. If you're a biotech investor, retail trader, or class action watcher this one’s for you. Expect sharp analysis, spicy quotes, and no sugarcoating.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
Visit ZLK.com for more info.

When a $5.3 billion merger with 3M’s Food Safety division was announced, investors expected a recipe for success. But instead, $NEOG stock plunged nearly 80% amid goodwill impairments, operational chaos, and a CEO exit. In this episode of Sue Wall Street, Cassie and Bill break down the class action lawsuit against Neogen Corporation and what went wrong behind the scenes. Perfect for retail investors, financial sleuths, and anyone tracking corporate accountability. Expect deep dives, sharp banter, and SEC-level drama.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
Visit ZLK.com for more info.

What happens when a clean energy giant promises reliable returns—then cuts all payouts overnight? In this episode of Sue Wall Street: Holding Wall Street Accountable, Cassie and Bill dig into the class action lawsuit against XPLR Infrastructure ($XIFR). Learn how risky financing, vague reassurances, and a surprise distribution halt led to a 35% crash and allegations of securities fraud. Perfect for dividend investors, ESG watchers, and anyone tracking the renewable energy sector.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
Visit ZLK.com for more info.

Layoffs, a failed $AMZN merger, and a collapsing business model—this episode of Sue Wall Street: Holding Wall Street Accountable dives deep into the class action lawsuit against iRobot ($IRBT). Cassie and Bill unpack how post-merger optimism gave way to massive losses, skipped earnings calls, and a 51% stock crash. Perfect for retail investors, legal buffs, and anyone tracking tech-sector red flags. Expect sharp commentary, financial drama, and one robot that couldn’t clean up its mess.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
Visit ZLK.com for more info.

Petco ($WOOF) promised a premium pet experience—but investors got a bargain-bin disaster. In this episode of Sue Wall Street: Holding Wall Street Accountable, Cassie and Bill dig into the class action lawsuit against Petco, unraveling how the company’s shift from upscale to value brands blindsided shareholders. Perfect for retail investors, legal watchers, and anyone following post-pandemic stock fallout. Expect deep dives, sharp analysis, and brutal stock chart drops.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
Visit ZLK.com for more info.

Description: In this episode of Sue Wall Street Holding Wall Street Accountable, Cassie and Bill break down the red flags of corporate fraud that could quietly wreck your investments. From shady earnings reports to sudden CFO resignations and sketchy auditors, learn how to safeguard your portfolio against hidden risks. Perfect for retail investors, finance enthusiasts, and anyone serious about protecting their wealth. Expect sharp insights, real-world examples, and straight talk. 
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
Visit ZLK.com for more info.

One company’s fraud can trigger a global meltdown. In this episode of Bulls & Betrayal: Holding Wall Street Accountable, Anna and Nate uncover how corporate scandals like $ENRN and the 2008 crash caused trillions in damage to the global economy. Perfect for investors, analysts, and finance-curious minds, this episode breaks down ripple effects—from lost jobs to regulatory overhauls. Expect sharp storytelling, real-world case studies, and hard truths.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
Visit ZLK.com for more info.